02 May 2003 : Original article
Peroxynitrite-PARP-1 pathway in traumatic brain injury in rats
V. Besson, N. Croci, R. Boulu, M. Plotkine, C. Marchand-VerrecchiaMed Sci Monit 2003; 9(1): 3-0 :: ID: 14988
Abstract
Background:Nitric oxide and free radicals contribute to injury elicited by traumatic brain injury (TBI) [1,2]. Peroxynitrite, resulting from the combination of nitric oxide and superoxide anion triggers DNA strand breakage, leading to the activation of poly(ADP-ribose)polymerase-1 (PARP-1) [3]. As excessive activation of this enzyme induces cell death, we examine the implication of peroxynitrite-PARP-1 pathway in the post-traumatic outcomes of focal TBI caused by fluid percussion on rats [4]. Material/Methods:In a first experiment, animals were killed 30 min, 2, 4, 6, 24, 48 and 72h after TBI for immunohistochemistry of a) 3-nitrotyrosine as a footprint of peroxynitrite production and b) poly(ADP-ribose) as a marker of PARP-1 activation. In a second experiment, the effect of 3-aminobenzamide (3-AB), a widely used PARP inhibitor, was investigated on the neurological deficit, the cerebral lesion and the activation of PARP-1. Rats were given 3-AB (10 and 30 mg/kg, i.p.) or its vehicle 30 min before, and 24, 48 and 72h after TBI. Results: Immunohistochemistry showed that 3-nitrotyrosine and poly(ADP-ribose) were present as early as 30 min post-injury, and persisted for 72h. Treatment with 3-AB significantly decreased the neurological deficit, the cerebral lesion and the poly(ADP-ribose) staining induced by TBI. Conclusions: The present study indicates that TBI induces peroxynitrite production associated with PARP-1 activation. Treatment with 3-AB, a PARP inhibitor, decreases the neurological deficit, the cerebral lesion and the PARP-1 activation caused by TBI. Thus, PARP-1 is involved in the pathogenesis of TBI and may be a promising therapeutic target for the treatment of brain trauma.References: 1.Mésenge C et al: J Neurotrauma, 1996; 13: 209-214 2.Mésenge C et al: J Pineal Res, 1998; 25: 41-46 3.Virág L, Szabó C: Pharmacol Rev, 2002; 54: 375-429 4.Toulmond S et al: Brain Res, 1993; 620: 24-31
Keywords: 3-nitrotyrosine, 3-aminobenzamide, neuroprotection, poly(ADP-ribose)polymerase-1, peroxynitrite, traumatic brain injury
Editorial
01 April 2025 : Editorial
Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to HumansDOI: 10.12659/MSM.949109
Med Sci Monit 2025; 31:e949109
In Press
Clinical Research
Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.947630
Clinical Research
Longitudinal Evaluation of Metabolic Benefits of Inactivated COVID-19 Vaccination in Diabetic Patients in T...Med Sci Monit In Press; DOI: 10.12659/MSM.947450
Clinical Research
Impact of Voltage Level on Hospitalization and Mortality in Electrical Injury Cases: A Retrospective Analys...Med Sci Monit In Press; DOI: 10.12659/MSM.947675
Clinical Research
Comparative Study of Plantar Load and Foot Posture Characteristics in Male Elite Squash Players and Non-Ath...Med Sci Monit In Press; DOI: 10.12659/MSM.947828
Most Viewed Current Articles
17 Jan 2024 : Review article 8,044,083
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,972
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 30,118
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 24,024
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912